Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026
Assembly Biosciences reported favorable Phase 1a clinical trial results for its investigational drug ABI-6250, demonstrating safety, tolerability, and effective target engagement in healthy participants. The oral NTCP inhibitor showed dose-dependent and reversible bile acid increases without serious adverse events. These promising findings support …